EVAX Evaxion Biotech A/S
USHealthcareAs of 2026-07-10 16:00
Why EVAX matters now
Evaxion Biotech A/S (EVAX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.17 with -0.94% on the session and $20.0M in market capitalization; recent performance reads 1-month -23.37% and YTD -36.06%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.6M, and EPS of $-0.44. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.0%.
The latest indexable market news headline is "Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.50; recent insider activity includes Bitsch-Norhave Jens filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.49
P/S
2.56
EV/EBITDA
-0.33
DCF Value
$36.42
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-122.0%
Net Margin
-129.6%
ROE
-77.8%
ROA
-34.4%
ROIC
-33.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.6M | $-0.44 |
| Q4 2025 | $0.00 | $-5.9M | $-0.89 |
| FY 2025 | $7.5M | $-7.7M | $-1.21 |
| Q3 2025 | $7.5M | $4.6M | $4.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.50
Target (Median)
$9.50
Target Range
$9.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
DK
Exchange
—
Beta
0.23
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.